d-tyrosine

D-Tyrosine, the D-isomer of tyrosine, acts as a negative regulator of melanin synthesis by inhibiting tyrosinase activity. Furthermore, D-Tyrosine also inhibits biofilm formation and induces the self-dispersal of biofilms, while not affecting bacterial growth.

H-D-Tyr(Propargyl)-OH is a click chemistry reagent that contains an Alkyne group, allowing it to undergo a copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules that possess an Azide group. This compound is specifically designed for applications involving azide-containing compounds.

NB-caged Tyrosine hydrochloride is a L-Tyrosine caged with photosensitiveortho-nitrobenzyl side chain. Rapidly releases tyrosine when photolyzed (300-350 nm excitation). Is readily incorporated intoE.coliproteins via inclusion in growth media.

7-BIA is a receptor-type protein tyrosine phosphatase D (PTPRD) inhibitor with anti-addictive properties, and is utilized in neuropathic pain research.

Vidarabine (Adenine Arabinoside) is a nucleoside antibiotic isolated from Streptomyces antibioticus. It has some antineoplastic properties and has broad spectrum activity against DNA viruses in cell cultures and significant antiviral activity against infections caused by a variety of viruses such as the herpes viruses, the VACCINIA VIRUS and varicella zoster virus.

(S)-2-Hydroxy-3-phenylpropanoic acid (L-(−)-3-Phenyllactic acid) is a chiral aromatic compound involved in phenylalanine metabolism. It is likely produced from phenylpyruvate via lactate dehydrogenase. The D-form is derived from bacterial sources, while the L-form is endogenous. Phenyllactate levels are normally very low in blood or urine, but high levels indicate phenylketonuria (PKU) and hyperphenylalaninemia (HPA). PKU is due to a deficiency of phenylalanine hydroxylase (PAH), causing phenylalanine to convert to phenylpyruvic acid rather than tyrosine.

ST271 is an effective protein tyrosine kinase (PTK) inhibitor.

D-69491 hydrochloride is an inhibitor of HER-2 tyrosine kinase activity, blocking the phosphorylation of HER-2 and inhibiting the proliferation of SKOV-3 cells. It exhibits antitumor activity.

D-65476 is a type III receptor tyrosine kinase (Flt3) inhibitor. It inhibits the proliferation of TEL-Flt3 transfected BA/F3 cells in the absence of IL-3, with an IC50 of 0.2 μM, and is useful for researching Flt3-driven leukemia.

Hirudin (54-65; non-sulfated) is a desulfated peptide fragment of hirudin, an anticoagulant produced byH. medicinalis.1It inhibits fibrin clot formation induced by isolated bovine thrombin with an IC50value of 3.7 μM.2 1.Niehrs, C., Huttner, W.B., Carvallo, D., et al.Conversion of recombinant hirudin to the natural form by in vitro tyrosine sulfation. Differential substrate specificities of leech and bovine tyrosylprotein sulfotransferasesJ. Biol. Chem.265(16)9314-9318(1990) 2.Payne, M.H., Krstenansky, J.L., Yates, M.T., et al.Positional effects of sulfation in hirudin and hirudin PA related anticoagulant peptidesJ. Med. Chem.34(3)1184-1187(1991)

Protein tyrosine phosphatases (PTPs) remove phosphate from tyrosine residues of cellular proteins. Reversible phosphorylation catalyzed by the coordinated actions of protein tyrosine kinases and phosphatases is key to the regulation of the signaling events that control cell growth and proliferation, differentiation, and survival or apoptosis, as well as adhesion and motility. RK-682, a bioactive compound originally isolated from the fermentation of Streptomyces sp. 88-682, is an inhibitor of the PTPs. It inhibits the phosphorylation of CD45 and VHR with IC50 values of 54 and 2 μM, respectively, and arrests cell cycle progress at the G1/S transition. It is also reported to inhibit heparanase (IC50 = 17 μM), an endo-β-D-glucuronidase involved in tumor cell invasion and angiogenesis. RK-682 (calcium salt) is a less soluble version of the free acid.

L-Tyrosine-13C9,15N is intended for use as an internal standard for the quantification of L-tyrosine by GC- or LC-MS. L-Tyrosine is a non-essential amino acid.1It is produced by hydroxylation of phenylalanine by phenylalanine hydroxylase but can also be obtained from dietary sources or degradation of endogenous proteins, resulting in L-tyrosine release.1,2L-Tyrosine is a precursor in the biosynthesis of catecholamine neurotransmitters, melanins, and thyroid hormones.3Plasma, skeletal muscle, and erythrocyte levels of L-tyrosine are decreased in patients with chronic kidney disease.1 1.Kopple, J.D.Phenylalanine and tyrosine metabolism in chronic kidney failureJ. Nutr.137(6 Suppl 1)1586S-1590S(2007) 2.Webster, D., and Wildgoose, J.Tyrosine supplementation for phenylketonuriaCochrane DB Syst. Rev.2013(6)CD001507(2013) 3.Slominski, A., and Paus, R.Towards defining receptors for L-tyrosine and L-DOPAMol. Cell Endocrinol.99(2)C7-C11(1994)

Potent EGFR-kinase inhibitor (IC50 = 0.7 nM). Displays >3000-fold selectivity against a panel of serine/threonine kinases. Reduces metastasis and angiogenesis in a mouse model of pancreatic cancer. Antihypertensive and orally bioavailable. Bruns et al (2000) Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res. 60 2926 PMID:10850439 |Ulu et al (2013) Epidermal growth factor receptor inhibitor PKI-166 governs cardiovascular protection without beneficial effects on the kidney in hypertensive 5/6 nephrectomized rats. J.Pharmacol.Exp.Ther. 345 393 PMID:23528611 |Kaspersen et al (2012) Activity of 6-aryl-pyrrolo[2,3-d]pyrimidine-4-amines to Tetrahymena. Bioorg.Chem. 44 35 PMID:22832269

Vascular endothelial growth factor receptor 2 (VEGFR2, also known as KDR and FLK1) is a receptor tyrosine kinase that regulates angiogenesis, vascular development, and embryonic hematopoiesis in response to VEGF isoforms A, C, and D. VEGFR2 kinase inhibitor II is a reversible, cell-permeable inhibitor of VEGFR2's kinase activity (IC50 = 70 nM). It less potently inhibits the platelet-derived growth factor receptor β (PDGFRβ; IC50 = 920 nM) and related receptor and non-receptor tyrosine kinases. VEGFR2 kinase inhibitor II blocks the growth of human umbilical vein endothelial cells stimulated with either VEGF or PDGF (IC50s = 110 nM and 2 μM, respectively).

Rhein-8-O-beta-D-glucopyranoside(Rhein-8-glucoside calcium (Rhein-8-glucoside calcium salt) salt) shows moderate bioactivity against human Protein Tyrosine Phosphatase 1B (hPTP1B) in vitro.

Befotertinib (D-0316) is an inhibitor of EGFR tyrosine kinase and can be used for studies about EGFR T790M-positive non-small cell lung cancer.

Licochalcone D may be a potential drug for human melanoma treatment by inhibiting proliferation, inducing apoptosis via the mitochondrial pathway and blocking cell migration and invasion. Licochalcone D has cardioprotective potential against myocardial is

D-Leu-Ty hydrate ((S)-2-((R)-2-Amino-4-methylpentanamido)-3-(4-hydroxyphenyl)propanoic acid hydrate) is a tyrosine derivative commonly used in drug synthesis and biochemistry research.

LY2457546 is a potent and orally bioavailable inhibitor of multiple receptor tyrosine kinases involved in angiogenic and tumorigenic signalling. LY2457546 demonstrates potent activity against targets that include VEGFR2 (KDR), PDGFRβ, FLT-3, Tie-2 and members of the Eph family of receptors. In vivo, LY2457546 inhibited VEGF-driven autophosphorylation of lung KDR in the mouse and rat in a dose and concentration dependent manner. LY2457546 was well tolerated and exhibited efficacy in a 13762 syngeneic rat mammary tumor models. Additionally, LY2457546 caused complete regression of well-established tumors in an acute myelogenous leukemia (AML) FLT3-ITD mutant xenograft tumor model. The unique spectrum of target activity, potent in vivo anti-tumor efficacy in a variety of rodent and human solid tumor models, exquisite potency against a clinically relevant model of AML, and non-clinical safety profile justify the advancement of LY2457546 into clinical testing. (source: Invest New D......

Rubrofusarin 6-O-β-D-glucopyranoside, a glycosidic derivative of Rubrofusarin, functions as an inhibitor of protein tyrosine phosphatase 1B (PTP1B) with an IC50 value of 87.36 μM, and is utilized in research investigating comorbid diabetes and depression [1].

Morin 3-O-β-D-glucopyranoside, a natural flavonoid, exhibits antifungal, anticancer, and antioxidant properties. This compound also inhibits reverse transcriptase, protein-tyrosine kinase, and xanthine oxidase, while demonstrating anti-HIV, antiarteriosclerotic, and superoxide scavenging activities [1].

Ibrutinib deacryloylpiperidine (IBT4A) is a highly selective Bruton's tyrosine kinase (BTK) irreversible inhibitor with an IC50 of 0.5 nM.

The impact of spleen tyrosine kinase (Syk) signaling might be prominent in lupus because (i) Syk is a shared downstream signaling molecule among circulating immune complex, LPS, and (1→3)-β-D-glucan (BG), and (ii) all of these factors are detectable in the serum of Fc gamma receptor IIb-deficient (FcgRIIb-/-) mice with sepsis. Syk inhibition downregulated several inflammatory pathways in FcgRIIb-/- macrophages activated with BG + LPS suggesting the potential anti-inflammatory impact of Syk inhibitors in lupus. Indeed, administration of a Syk inhibitor prior to cecal ligation and puncture (CLP) sepsis in FcgRIIb-/- mice reduced baseline lupus-induced proinflammatory cytokines and attenuated sepsis severity as evaluated by mortality, organ injury, serum LPS, and post-sepsis serum cytokines.

Hibarimicin D is a tyrosine kinase inhibitor that selectively inhibits the activity of src tyrosine kinase. Additionally, Hibarimicin D exhibits moderate activity against Gram-positive bacteria, with a MIC range of 0.8-12.56 μg/mL.